The development of polyanhydrides for drug delivery applications.
This paper reviews the development of the polyanhydrides as bioerodible polymers for drug delivery applications. The topics include design and synthesis of the polymer, physical properties, techniques to fabricate the polymer into drug delivery devices, evaluation of biocompatibility, and example applications of the polyanhydrides. Discussion of the interrelationship between the physical-chemical properties of the polyanhydrides, fabrication methods, and drug release rates is included. One section is devoted to a case study to provide a historical perspective of the development a polyanhydride-based drug delivery treatment from the conception of the idea to the final stages of human clinical trials. This section includes an outline of the extensive in vitro and in vivo testing that is necessary for development of a new material for biomedical applications.
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge 02139.
J
J
Tamada
R
R
Langer
D000544:Alzheimer Disease / Q000188:drug therapy; D000812:Anhydrides / Q000138:chemical synthesis / Q000737:chemistry; D000818:Animals; D018723:Bethanechol; D001626:Bethanechol Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D001672:Biocompatible Materials; D001673:Biodegradation, Environmental; D001932:Brain Neoplasms / Q000188:drug therapy / Q000628:therapy; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical / Q000379:methods; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003652:Decanoic Acids / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D004304:Dosage Forms; D016503:Drug Delivery Systems; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D015394:Molecular Structure; D010019:Osteomyelitis / Q000188:drug therapy; D011091:Polyesters / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity; D011108:Polymers / Q000138:chemical synthesis / Q000737:chemistry; D051381:Rats; D011916:Rats, Inbred F344; D011919:Rats, Inbred Strains; D013678:Technology, Pharmaceutical / Q000379:methods
D000812:Anhydrides; D001626:Bethanechol Compounds; D001672:Biocompatible Materials; D003652:Decanoic Acids; D004304:Dosage Forms; D005839:Gentamicins; D007328:Insulin; D011091:Polyesters; D011108:Polymers; D018723:Bethanechol; C055401:decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; D002330:Carmustine